Securekloud's Healthcare Triangle enables secure data sharing for drug discovery via Neutral Zone

6 Jul 2022 , 02:03 PM

Securekloud’s Healthcare Triangle Inc. allows for collaborative data sharing and analysis via a “neutral zone” Personalized medicine in healthcare and life sciences is being revolutionized by a neutral zone for data collaborative research.

From the discovery of a key enzyme that allows DNA sequencing to the discovery of a “treasure trove” of DNA clues about what causes cancer, reflects that medical Science advancements have the potential to propel personalized medicine.

The key to this effort is the ability to share data among competitors in order to fuel healthcare innovation. The use of a “neutral zone,” supported by DataEz, a third-party secure data platform provider for collaborative data sharing and analysis, now allows organizations to collaborate on medical discovery without jeopardizing PHI security.

With a neutral zone, innovation is no longer solely dependent on one company’s ability to capture and analyze data. Organizations instead collaborate with a third-party algorithm provider to create a secure environment in which AI, machine learning, and other advanced algorithms can be applied to data.

It’s a strategy that safeguards data security as well as each organization’s intellectual property (IP). It also positions organizations to take advantage of the power of patient data at scale, both their own and that of data research collaborators.

“There is a market need for a third-party organization to act as the ‘glue’ that connects the other parties for collaborative research and analysis in a neutral setting. These companies are uninterested in each other’s data. They’re curious about the insights that can be gleaned from pooling their data for AI analysis. That is the value of a neutral zone built on the DataEz platform,” Anand Kumar, Senior Vice President – Head of Cloud Solutions, Healthcare Triangle, says.

At around 2.07 PM, SecureKloud was trading at Rs73.80, down by 0.67% against its previous close of Rs74.30 on NSE.